Asia Pacific Cold Sore Treatment Market
市场规模(十亿美元)
CAGR : %
Forecast Period |
2021 –2028 |
Market Size (Base Year) |
USD 116.71 Million |
Market Size (Forecast Year) |
USD 198.29 Million |
CAGR |
|
Major Markets Players |
>亚太唇疱疹治疗市场,按病毒株类型(单纯疱疹 1 型病毒和单纯疱疹 2 型病毒)、治疗药物(抗病毒药物、止痛药及其他药物)、药物类型(品牌药物和仿制药)、剂量类型(口服、外用及其他药物)、最终用户(医院、家庭护理、专科诊所及其他)、分销渠道(医院药房、零售药房、网上药房及其他)、国家(日本、中国、澳大利亚、印度、韩国、新加坡、印度尼西亚、泰国、马来西亚、菲律宾、越南、亚太其他地区)划分的行业趋势和预测(至 2028 年)
市场分析与洞察:亚太地区唇疱疹治疗市场
预计在 2021 年至 2028 年的预测期内,唇疱疹治疗市场将实现市场增长。Data Bridge Market Research 分析称,在 2021 年至 2028 年的预测期内,该市场将以 7.2% 的复合年增长率增长,预计到 2027 年将从 2020 年的 1.1671 亿美元增至 1.9829 亿美元。
全球单纯疱疹病毒 (HSV) 患病率上升、HSV 传播方式的扩散、技术进步和发展的不断加快是预测期内推动市场需求的主要驱动力。
唇疱疹或口腔疱疹是由于单纯疱疹病毒 (HSV) 感染而出现的类似擦伤的小水疱。唇疱疹通常发生在面部、嘴唇周围、下巴、脸颊和鼻孔。它们通常会在破裂前引起疼痛、瘙痒。HSV 是影响全球人口的最常见病毒之一,在世界各地流行。全世界多达 90% 的人至少患有一种形式的 HSV。
单纯疱疹病毒 (HSV) 通常感染全球儿童人群,但根据世界卫生组织 (WHO) 的数据,30-49 岁的人现在感染病毒的风险更高,并且 HSV 的患病率随着年龄的增长而增加。HSV 有两种类型:HSV 1 型和 HSV 2 型。HSV-1 会导致嘴唇、鼻孔和脸颊周围出现唇疱疹或口腔疱疹。而 HSV-2 会导致生殖器疱疹。HSV 可以通过直接传播方式传播,包括口腔接触诱发口腔疱疹感染,从口腔到看似正常且没有症状的皮肤表面。
唇疱疹治疗市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息,分析了新兴收入领域、市场法规变化、产品审批、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情况,请联系我们获取分析师简报,我们的团队将帮助您创建收入影响解决方案,以实现您的预期目标。
亚太地区唇疱疹治疗市场范围和市场规模
根据菌株类型、治疗类型、药物类型、剂量类型、最终用户和分销渠道,唇疱疹治疗市场可分为六个显著的部分。
- 根据病毒株类型,唇疱疹治疗市场分为 1 型单纯疱疹病毒和 2 型单纯疱疹病毒。2021 年,1 型单纯疱疹病毒 (HSV) 因其流行率迅速上升而占据市场主导地位。
- 根据治疗类型,唇疱疹治疗市场分为抗病毒药物、镇痛药物和其他药物。2021 年,由于单纯疱疹病毒引起的传染病数量增加,预计抗病毒药物将主导唇疱疹治疗市场,而抗病毒药物产品线的增强预计将主导市场。
- 根据药物类型,唇疱疹治疗市场分为品牌药和仿制药。2021 年,仿制药在唇疱疹治疗市场占据主导地位,因为与品牌药相比,仿制药非常便宜,而且经济实惠,在唇疱疹治疗中的使用量增加。
- 根据剂型,唇疱疹治疗市场分为口服、外用和其他。2021 年,口服剂型预计将在唇疱疹治疗市场占据主导地位,因为它易于吸收,并且能够灵活地适应各种类型的药物。
- 根据最终用户,唇疱疹治疗市场分为医院、家庭护理、专科诊所和其他。2021 年,由于在家治疗方便且药物容易获得,家庭护理领域占据市场主导地位。
- 根据分销渠道,唇疱疹治疗市场分为医院药房、零售药房和网上药房。预计到 2021 年,医院药房将占据市场主导地位,因为唇疱疹药物的可获得性增加,并且每日唇疱疹药物处方数量激增,预计将占据市场主导地位。
唇疱疹治疗市场国家层面分析
对唇疱疹治疗市场进行分析,市场规模信息基于菌株类型、治疗用途、药物类型、剂量类型、最终用户和分销渠道。
唇疱疹治疗市场报告涉及的国家包括日本、中国、澳大利亚、印度、韩国、新加坡、印度尼西亚、泰国、马来西亚、菲律宾、越南和亚太地区其他地区。
预计亚太地区的日本将在预测期内以最快的复合年增长率增长,因为亚太地区国家对唇疱疹治疗的需求因患者人数的快速增加和技术的进步而迅速增加。
报告的国家部分还提供了影响单个市场因素和国内市场法规变化,这些变化影响了市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外,在提供国家数据的预测分析时,还考虑了亚太品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战、销售渠道的影响。
制造商的战略举措为唇疱疹治疗市场参与者创造了新的机会
唇疱疹治疗市场还为您提供每个国家美容行业增长的详细市场分析,包括唇疱疹治疗销售、唇疱疹治疗进步的影响以及监管环境的变化及其对唇疱疹治疗市场的支持。数据涵盖 2011 年至 2019 年的历史时期。
竞争格局和唇疱疹治疗市场份额分析
唇疱疹治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对唇疱疹治疗市场的关注有关。
提供唇疱疹治疗的主要公司有 Merix Pharmaceutical Corp.、GlaxoSmithKline plc、Amneal Pharmaceuticals LLC、Sun Pharmaceutical Industries Ltd.、Glenmark Pharmaceutical Inc., USA (A Subsidiary OF Glenmark Pharmaceuticals Ltd.)、Zydus Pharmaceuticals, Inc.(A Subsidiary of Zydus Cadila)、Cipla Inc.、AiCuris、Ortho dermatologics' (a division of Bausch Health Companies Inc.)、Foundation Consumer Healthcare、Squarex、Teva Pharmaceuticals USA, Inc. (a Subsidiary of Teva Pharmaceutical Industries Ltd.)、Aurobindo Pharma USA (A Subsidiary of Aurobindo Pharma)、WOCKHARDT、Novartis AG、Jubilant Cadista (a Subsidiary of Jubilant Life Sciences Limited)、Hikma Pharmaceuticals PLC、Hetero Healthcare Limited、Apotex Inc.、Avanir Pharmaceuticals, Inc.、HRA Pharma 等等。 DBMR 分析师了解竞争优势并为每个竞争对手分别提供竞争分析。
全球各地的公司也推出了许多产品并签署了多项协议,这也加速了唇疱疹治疗市场的发展。
- 2020 年 2 月,Ortho Dermatologics 宣布在美国推出首个非报销处方皮肤科远程医疗平台 dermatology.com,这将帮助患者咨询医生和订购网站上提供的品牌皮肤科产品。这将有助于公司扩大业务并增强产品形象。
市场参与者的合作、合资和其他策略正在增强公司在唇疱疹治疗市场中的市场,这也为组织改善其在唇疱疹治疗方面的产品提供了好处。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC COLD SORE TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 THERAPEUTICS LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET DRUG TYPE COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS
5 EPIDEMIOLOGY
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING PREVALENCE OF COLD SORE INFECTION
6.1.2 PROLIFERATION IN MODES OF TRANSMISSION OF HERPES SIMPLEX VIRUS
6.1.3 INCREASING AWARENESS ABOUT SEXUALLY TRANSMITTED DISEASES
6.1.4 AVAILABILITY OF GENERIC DRUGS
6.1.5 RISING RATE OF HSV INFECTION AMONG WOMEN
6.2 RESTRAINTS
6.2.1 PATENT TERMINATION OF MARKETED DRUGS
6.2.2 RISKS OF OTHER DISEASES ASSOCIATED WITH COLD SORE
6.2.3 DEARTH OF AWARENESS ABOUT THE ONSET AND SYMPTOMS OF COLD SORE TREATMENT
6.3 OPPORTUNITIES
6.3.1 INCREASING DISPOSABLE INCOME
6.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
6.3.3 INCREASING RESEARCH AND DEVELOPMENT
6.3.4 INCREASING USE OF COLD SORE PATCHES
6.4 CHALLENGES
6.4.1 RISE IN ALTERNATIVE TREATMENTS
6.4.2 EMERGENCE OF DRUGS RESISTANT TO ACYCLOVIR
6.4.3 SIDE EFFECTS ASSOCIATED WITH MEDICATIONS USED FOR TREATING COLD SORE
7 COVID-19 IMPACT ON ASIA-PACIFIC COLD SORE TREATMENT MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY CHAIN
7.4 STRATEGIC DECISIONS FOR MANUFACTURERS
7.5 CONCLUSION
8 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY STRAIN TYPE
8.1 OVERVIEW
8.2 HERPES SIMPLEX TYPE 1 VIRUS
8.3 HERPES SIMPLEX TYPE 2 VIRUS
9 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY THERAPEUTICS
9.1 OVERVIEW
9.2 ANTIVIRAL AGENTS
9.2.1 ACYCLOVIR
9.2.2 FAMCICLOVIR
9.2.3 PENCICLOVIR
9.2.4 VALACYCLOVIR
9.2.5 DOCOSANOL
9.3 ANALGESIC AGENTS
9.3.1 CARMEX
9.3.2 HERPECIN
9.3.3 OTHERS
9.4 OTHERS
10 ASIA-PACIFIC COLD SORETREATMENT MARKET, BY DRUG TYPE
10.1 OVERVIEW
10.2 GENERICS
10.2.1 OTC
10.3 BRANDED
10.3.1 PRESCRIPTION
10.3.2 OTC
11 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY DOSAGE TYPE
11.1 OVERVIEW
11.2 ORAL
11.3 TABLETS
11.4 PILLS
11.5 TOPICAL
11.5.1 CREAM
11.5.2 OINTMENTS
11.5.3 GEL
11.5.4 SPRAY
11.6 OTHERS
12 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY END USER
12.1 OVERVIEW
12.2 HOME CARE
12.3 HOSPITALS
12.4 SPECIALTY CLINICS
12.5 OTHERS
13 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 HOSPITALS PHARMACY
13.3 ONLINE PHARMACY
13.4 RETAIL PHARMACY
14 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY GEOGRAPHY
14.1 ASIA PACIFIC
14.1.1 CHINA
14.1.2 JAPAN
14.1.3 INDIA
14.1.4 AUSTRALIA
14.1.5 SOUTH KOREA
14.1.6 SINGAPORE
14.1.7 MALAYSIA
14.1.8 PHILIPPINESS
14.1.9 INDONESIA
14.1.10 THAILAND
14.1.11 VIETNAM
14.1.12 REST OF ASIA-PACIFIC
15 ASIA-PACIFIC COLD SORE TREATMENT MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16 SWOT
17 COMPANY PROFILE
17.1 GLAXOSMITHKLINE PLC
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.2 ORTHO DERMATOLOGICS’ (A DIVISION OF BAUSCH HEALTH COMPANIES INC.)
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 FOUNDATION CONSUMER HEALTHCARE
17.3.1 COMPANY SNAPSHOT
17.3.2 COMPANY SHARE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 RECENT DEVELOPMENT
17.4 NOVARTIS AG
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENTS
17.6 AMNEAL PHARMACEUTICALS LLC
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENTS
17.7 AICURIS GMBH & CO. KG
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENTS
17.8 APOTEX INC.
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENTS
17.9 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA)
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENTS
17.1 CIPLA LIMITED
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENTS
17.11 GLENMARK PHARMACEUTICALS, INC., USA (A SUBSIDIARY OF GLENMARK PHARMACEUTICAL LTD.)
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENTS
17.12 HIKMA PHARMACEUTICALS PLC
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENTS
17.13 HRA PHARMA
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENTS
17.14 HETERO HEALTHCARE LIMITED
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.15 JUBILANT CADISTA (A SUBSIDIARY OF JUBILANT LIFE SCIENCES LIMITED)
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENT
17.16 MERIX PHARMACEUTICAL CORP.
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENTS
17.17 SQAUREX
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 SUN PHARMACEUTICAL INDUSTRIES LTD.
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENTS
17.19 VIATRIS INC.
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENTS
17.2 WOCKHARDT
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENTS
17.21 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
表格列表
LIST OF TABLES
TABLE 1 ASIA-PACIFICCOLD SORE TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 GENERIC DRUGS USED FOR THE TREATMENT OF HSV (COLD SORES)
TABLE 3 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 4 ASIA-PACIFIC HERPES SIMPLEX TYPE 1 VIRUS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 ASIA-PACIFIC HERPES SIMPLEX TYPE 2 VIRUS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY THERAPEUTICS 2019-2028 (USD MILLION)
TABLE 7 ASIA-PACIFIC ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY REGION 2019-2028 (USD MILLION)
TABLE 8 ASIA-PACIFIC ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 9 ASIA-PACIFIC ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 ASIA-PACIFIC ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC OTHERS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY DRUG TYPE 2019-2028 (USD MILLION)
TABLE 13 ASIA-PACIFIC GENERICS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 ASIA-PACIFIC GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 15 ASIA-PACIFIC BRANDED IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 ASIA-PACIFIC BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 17 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY DOSAGE TYPE 2019-2028 (USD MILLION)
TABLE 18 ASIA-PACIFIC ORAL IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 ASIA-PACIFIC ORAL SEGMENT IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 20 ASIA-PACIFIC TOPICAL SEGMENT IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 ASIA-PACIFIC TOPICAL SEGMENT IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 22 ASIA-PACIFIC OTHERS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 24 ASIA-PACIFIC HOSPITALS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 ASIA-PACIFIC HOSPITALS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 ASIA-PACIFIC SPECIALTY CLINICS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 ASIA-PACIFIC OTHERS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 29 ASIA-PACIFIC HOSPITALS PHARMACY IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 ASIA-PACIFIC ONLINE PHARMACY IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 ASIA-PACIFIC RETAIL PHARMACY IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 ASIA PACIFIC COLD SORE MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 33 ASIA PACIFIC COLD SORE MARKET, BY STRAIN, 2019-2028 (USD MILLION)
TABLE 34 ASIA PACIFIC COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 35 ASIA PACIFIC ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 36 ASIA PACIFIC ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 37 ASIA PACIFIC COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 38 ASIA PACIFIC GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 39 ASIA PACIFIC BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 40 ASIA PACIFIC COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 41 ASIA PACIFIC ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 42 ASIA PACIFIC TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 43 ASIA PACIFIC COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 44 ASIA PACIFIC COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 45 CHINA COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 46 CHINA COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 47 CHINA ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 48 CHINA ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 49 CHINA COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 50 CHINA GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 51 CHINA BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 52 CHINA COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 53 CHINA ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 54 CHINA TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 55 CHINA COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 56 CHINA COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 57 JAPAN COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 58 JAPAN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 59 JAPAN ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 60 JAPAN ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 61 JAPAN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 62 JAPAN GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 63 JAPAN BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 64 JAPAN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 65 JAPAN ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 66 JAPAN TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 67 JAPAN COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 68 JAPAN COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 69 INDIA COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 70 INDIA COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 71 INDIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 72 INDIA ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 73 INDIA COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 74 INDIA GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 75 INDIA BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 76 INDIA COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 77 INDIA ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 78 INDIA TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 79 INDIA COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 80 INDIA COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 81 PERU COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 82 PERU COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 83 AUSTRALIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 84 AUSTRALIA ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 85 AUSTRALIA COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 86 AUSTRALIA GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 87 AUSTRALIA BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 88 AUSTRALIA COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 89 AUSTRALIA ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 90 AUSTRALIA TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 91 AUSTRALIA COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 92 AUSTRALIA COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 93 SOUTH KOREA COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 94 SOUTH KOREA COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 95 SOUTH KOREA ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 96 SOUTH KOREA ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 97 SOUTH KOREA COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 98 SOUTH KOREA GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 99 SOUTH KOREA BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 100 SOUTH KOREA COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 101 SOUTH KOREA ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 102 SOUTH KOREA TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 103 SOUTH KOREA COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 104 SOUTH KOREA COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 105 SINGAPORE COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 106 SINGAPORE COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 107 SINGAPORE ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 108 SINGAPORE ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 109 SINGAPORE COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 110 SINGAPORE GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 111 SINGAPORE BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 112 SINGAPORE COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 113 SINGAPORE ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 114 SINGAPORE TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 115 SINGAPORE COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 116 SINGAPORE COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 117 MALAYSIA COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 118 MALAYSIA COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 119 MALAYSIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 120 MALAYSIA ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 121 MALAYSIA COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 122 MALAYSIA GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 123 MALAYSIA BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 124 MALAYSIA COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 125 MALAYSIA ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 126 MALAYSIA TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 127 MALAYSIA COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 128 MALAYSIA COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 129 PHILIPPINESS COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 130 PHILIPPINESS COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 131 PHILIPPINESS ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 132 PHILIPPINESS ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 133 PHILIPPINESS COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 134 PHILIPPINESS GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 135 PHILIPPINESS BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 136 PHILIPPINESS COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 137 PHILIPPINESS ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 138 PHILIPPINESS TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 139 PHILIPPINESS COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 140 PHILIPPINESS COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 141 INDONESIA COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 142 INDONESIA COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 143 INDONESIA ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 144 INDONESIA ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 145 INDONESIA COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 146 INDONESIA GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 147 INDONESIA BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 148 INDONESIA COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 149 INDONESIA ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 150 INDONESIA TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 151 INDONESIA COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 152 INDONESIA COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 153 THAILAND COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 154 THAILAND COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 155 THAILAND ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 156 THAILAND ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 157 THAILAND COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 158 THAILAND GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 159 THAILAND BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 160 THAILAND COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 161 THAILAND ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 162 THAILAND TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 163 THAILAND COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 164 THAILAND COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 165 VIETNAM COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
TABLE 166 VIETNAM COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 167 VIETNAM ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)
TABLE 168 VIETNAM ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2019-2028 (USD MILLION)
TABLE 169 VIETNAM COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 170 VIETNAM GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 171 VIETNAM BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 172 VIETNAM COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 173 VIETNAM ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 174 VIETNAM TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)
TABLE 175 VIETNAM COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)
TABLE 176 VIETNAM COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 177 REST OF ASIA-PACIFIC COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)
图片列表
LIST OF FIGURES
FIGURE 1 ASIA-PACIFIC COLD SORE TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC COLD SORE TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC COLD SORE TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC COLD SORE TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC COLD SORE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC COLD SORE TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA-PACIFIC COLD SORE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC COLD SORE TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC COLD SORE TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC COLD SORE TREATMENT MARKET: MARKET DRUG TYPE COVERAGE GRID
FIGURE 11 ASIA-PACIFIC COLD SORE TREATMENT MARKET: SEGMENTATION
FIGURE 12 GROWING PREVALENCE OF COLD SORE TREATMENT WORLDWIDE, AND PROLIFERATION IN MODES OF TRANSMISSION OF HERPES SIMPLEX VIRUS (HSV), AND INCREASING AWARENESS ABOUT SEXUALLY TRANSMITTED DISEASES ARE DRIVING THE ASIA-PACIFIC COLD SORE TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 HERPES SIMPLEX TYPE 1 VIRUS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC COLD SORE TREATMENT MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC COLD SORE TREATMENT MARKET
FIGURE 15 PREVALENCE OF HERPES SIMPLEX VIRUS TYPE 1, AMONG PERSONS AGED 14-49 YEARS, BY AGE GROUP: IN THE U.S. 2015–2016
FIGURE 16 PREVALENCE OF HERPES SIMPLEX VIRUS TYPE 1, BY RACE AND HISPANIC ORIGIN: U.S. 2015–2016
FIGURE 17 PREVALENCE OF HERPES SIMPLEX VIRUS TYPE 1, BY SEX: IN DIFFERENT COUNTRIES 2015–2016
FIGURE 18 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY STRAIN TYPE, 2020
FIGURE 19 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY STRAIN TYPE, 2020-2028 (USD MILLION)
FIGURE 20 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY STRAIN TYPE, CAGR (2021-2028)
FIGURE 21 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY STRAIN TYPE, LIFELINE CURVE
FIGURE 22 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY THERAPEUTICS, 2020
FIGURE 23 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY THERAPEUTICS , 2020-2028 (USD MILLION)
FIGURE 24 ASIA-PACIFIC COLD SORETREATMENT MARKET: BY THERAPEUTICS, CAGR (2021-2028)
FIGURE 25 ASIA-PACIFIC COLD SORETREATMENT MARKET: BY THERAPEUTICS, LIFELINE CURVE
FIGURE 26 ASIA-PACIFIC COLD SORETREATMENT MARKET: BY DRUG TYPE, 2020
FIGURE 27 ASIA-PACIFIC COLD SORETREATMENT MARKET: BY DRUG TYPE 2020-2028 (USD MILLION)
FIGURE 28 ASIA-PACIFIC COLD SORETREATMENT MARKET: BY DRUG TYPE, CAGR (2021-2028)
FIGURE 29 ASIA-PACIFIC COLD SORETREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 30 ASIA-PACIFIC COLD SORETREATMENT MARKET: BY DOSAGE TYPE, 2020
FIGURE 31 ASIA-PACIFIC COLD SORETREATMENT MARKET: BY DOSAGE TYPE 2020-2028 (USD MILLION)
FIGURE 32 ASIA-PACIFIC COLD SORETREATMENT MARKET: BY DOSAGE TYPE, CAGR (2021-2028)
FIGURE 33 ASIA-PACIFIC COLD SORETREATMENT MARKET: BY DOSAGE TYPE, LIFELINE CURVE
FIGURE 34 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY END USER, 2020
FIGURE 35 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY END USER 2020-2028 (USD MILLION)
FIGURE 36 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY END USER, CAGR (2021-2028)
FIGURE 37 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 39 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2020-2028 (USD MILLION)
FIGURE 40 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 41 ASIA-PACIFIC COLD SORE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 ASIA PACIFIC COLD SORE TREATMENT MARKET: SNAPSHOT (2020)
FIGURE 43 ASIA PACIFIC COLD SORE TREATMENT MARKET: BY COUNTRY (2020)
FIGURE 44 ASIA PACIFIC COLD SORE TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 45 ASIA PACIFIC COLD SORE TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 46 ASIA PACIFIC COLD SORE TREATMENT MARKET: BY STRAINS (2021-2028)
FIGURE 47 ASIA-PACIFIC COLD SORE TREATMENT MARKET: COMPANY SHARE 2020 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.